Also known as: U.S. government, US government
Vaccine denial and weakened public health measures risk increasing chronic illness, as historical data shows post-infectious conditions follow major outbreaks. Long COVID affects 10-20% of those infected, while historical pandemics led to conditions like encephalitis lethargica with near 50% mortality.
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
President Donald Trump’s April 2, 2026 proclamation sets a 100% Section 232 tariff on certain patented pharmaceuticals and APIs from July 31, 2026. Generics, biosimilars and several specialty categories are exempt, while some companies can qualify for reduced or zero tariffs through onshoring or MFN pricing agreements.
German and Swiss pharmaceutical manufacturers warned that new US tariffs could threaten European production and research. Industry groups said the measures could disrupt medicine supply chains and shift investment to the US.
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Charles River Laboratories forecast 2026 adjusted profit of $10.70 to $11.20 per share, above Wall Street estimates, citing improved demand for drug discovery and development services from biotech clients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06179732 |
Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities |
COMPLETED | PHASE3 |
